Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TIOCONAZOLE FOR SYSTEM SUITABILITY CRS (50 MG)

TIOCONAZOLE FOR SYSTEM SUITABILITY CRS (50 MG)

65899-73-2

DISCOVER
FLUTICASONE PROPIONATE CRS (80 MG)

FLUTICASONE PROPIONATE CRS (80 MG)

80474-14-2

DISCOVER
B19 VIRUS DNA FOR NAT TESTINGBRP (150 MG)

B19 VIRUS DNA FOR NAT TESTINGBRP (150 MG)

NA

DISCOVER
CLONAZEPAM - REFERENCE SPECTRUM (N/A)

CLONAZEPAM - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
PIRACETAM CRS (150 MG)

PIRACETAM CRS (150 MG)

7491-74-9

DISCOVER
POLYSORBATE  20 - REFERENCE SPECTRUM (N/A)

POLYSORBATE 20 - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
POLYSORBATE  40 - REFERENCE SPECTRUM (N/A)

POLYSORBATE 40 - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
POLYSORBATE  60 - REFERENCE SPECTRUM (N/A)

POLYSORBATE 60 - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
TIOCONAZOLE - REFERENCE SPECTRUM (N/A)

TIOCONAZOLE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
THEOPHYLLINE - REFERENCE SPECTRUM (N/A)

THEOPHYLLINE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
MESALAZINE CRS (80 MG)

MESALAZINE CRS (80 MG)

89-57-6

DISCOVER
FLUPHENAZINE OCTANOATE CRS (20 MG)

FLUPHENAZINE OCTANOATE CRS (20 MG)

5002-47-1

DISCOVER